Episode 512: ENZA-P Nature Medicine translational data
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
The Uromigos
The Uromigos
Underwood and Flinch: A Vampire Saga
Mike Bennett
Alpha Casts - AI Market Intelligence
StockAlpha.ai
InSession Film Podcast
InSession Film
1-on-1 with DP – 93.7 The Ticket KNTK
BDP Communications
Invisible Histories
Cari Simson Elke Hautala
Roanoke News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The Turnbuckle Tavern
Turnbuckle Tavern
Zion Lutheran Church - Anoka, MN
Zion Lutheran Church
Sekulow
Jay Sekulow
The Erick Erickson Show
Erick Erickson
مصطفی ملکیان | Mostafa Malekian (official)
مؤسّسهیِ فرهنگیِ فرزانه
Chassé-croisé
France Inter
E2E: From Entry Level to Executive
American Staffing Association
MDAA Defense Briefing
Missile Defense Advocacy Alliance
Murder Files Unsealed
AC Wilson
AZ 12 Podcast
Michael Luke
LiSTNR Central Coast Local News
LiSTNR
Precision Animal Training
Kirsten Kraljevic
Fit Disciple Podcast
Adam Braud
The Last Trump
Pastor Mike Chorey & Kirk Space
Colt's corner
Cattway Mathewson
Tangle
Isaac Saul
Oklahoma City Thunder News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The Legal Podcast Network
The Legal Podcast Network (LPN)
The Missing Persons Report
AC Wilson
Scorecard
CBS Sports
Trafikredaktionen Stockholm
Sveriges Radio
Law and Legal | America Out Loud News
Law and Legal | America Out Loud News
Constitution | America Out Loud News
Constitution | America Out Loud News
America Out Loud News
America Out Loud News
DLLS Texas Rangers Podcast
DLLS Sports, ALLCITY Network
The Defiant
The Defiant
Southern Remedy
MPB Think Radio
Dover News Today | 2 Min News | The Daily News Now!
The Daily News Now!
UFO to UAP Podcast
Matt Tones
Tout
The Uromigos
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and ...
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent stud...
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and inn...
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts di...
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, c...
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of d...
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer a...
This session from APCCC 2026 features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in current practices, challenges, and future directions in radi...
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-dri...
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-ri...
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment d...
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
In the world of prostate cancer treatment, chemotherapy's role, especially in metastatic hormone-sensitive cases, remains a topic of much discussion and evolving understanding. In this podcast, we delve into the insights...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.